Mahesh K B Parmar
Overview
Explore the profile of Mahesh K B Parmar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
9169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noor N, Radford S, Choodari-Oskooei B, Gordon M, Hart A, Hepburn T, et al.
Nat Rev Gastroenterol Hepatol
. 2025 Mar;
PMID: 40045038
No abstract available.
2.
Leone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, et al.
JAMA Oncol
. 2025 Feb;
PMID: 40014335
No abstract available.
3.
Bedia J, Jacobs I, Ryan A, Gentry-Maharaj A, Burnell M, Singh N, et al.
EBioMedicine
. 2025 Jan;
112:105554.
PMID: 39808947
Background: The ovarian cancer (OC) preclinical detectable phase (PCDP), defined as the interval during which cancer is detectable prior to clinical diagnosis, remains poorly characterised. We report exploratory analyses from...
4.
Meade A, Frangou E, Choodari-Oskooei B, Larkin J, Powles T, Stewart G, et al.
Contemp Clin Trials Commun
. 2024 Nov;
42:101381.
PMID: 39555240
Clinical trials to establish the efficacy of new agents in the adjuvant cancer setting typically take many years to complete. During that time, external factors can impact recruitment and reporting...
5.
Pal S, Chataway J, Swingler R, Macleod M, Carragher N, Hardingham G, et al.
Lancet Neurol
. 2024 Sep;
23(11):1097-1107.
PMID: 39307154
Background: Motor neuron disease represents a group of progressive and incurable diseases that are characterised by selective loss of motor neurons, resulting in an urgent need for rapid identification of...
6.
Parker C, Clarke N, Cook A, Petersen P, Catton C, Cross W, et al.
Eur Urol
. 2024 Aug;
86(5):422-430.
PMID: 39217077
Background And Objective: The use and duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) have been uncertain. RADICALS-HD compared adding no ("None"), 6-months ("Short"), or 24-mo ("Long") ADT...
7.
Choodari-Oskooei B, Blenkinsop A, Handley K, Pinkney T, Parmar M
BMC Med Res Methodol
. 2024 Jul;
24(1):143.
PMID: 38956455
No abstract available.
8.
Choodari-Oskooei B, Blenkinsop A, Handley K, Pinkney T, Parmar M
BMC Med Res Methodol
. 2024 Jun;
24(1):124.
PMID: 38831421
Background: Multi-arm multi-stage (MAMS) randomised trial designs have been proposed to evaluate multiple research questions in the confirmatory setting. In designs with several interventions, such as the 8-arm 3-stage ROSSINI-2...
9.
Parker C, Clarke N, Cook A, Kynaston H, Catton C, Cross W, et al.
Lancet
. 2024 May;
403(10442):2405-2415.
PMID: 38763154
Background: Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of...
10.
Parker C, Kynaston H, Cook A, Clarke N, Catton C, Cross W, et al.
Lancet
. 2024 May;
403(10442):2416-2425.
PMID: 38763153
Background: Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with...